Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage

Nazari, Hossein; Modarres, Mehdi; Parvaresh, Mohammad; Ghasemi Falavarjani, Khalil
December 2010
Graefe's Archive of Clinical & Experimental Ophthalmology;Dec2010, Vol. 248 Issue 12, p1713
Academic Journal
Purpose: To evaluate outcomes of intravitreal injection of bevacizumab for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhages (VH or RH). Methods: This is a prospective interventional case-series. Fourteen eyes of eight premature infants with severe ROP associated with vitreous or retinal hemorrhage were consecutively included. In eight eyes, VH and/or RH precluding complete laser ablation developed at the time of laser treatment. In six eyes, VH developed early after laser ablation. All participants underwent intravitreal injection of 0.625 mg (0.025 ml) bevacizumab immediately after diagnosis of VH or RH. Follow-up examinations were performed at days 1, 3, 7, and 14, and 1, 2 and 3 months after injection. Main outcome measure was the absence of unfavorable structural outcomes. Results: Mean gestational age was 27.6 weeks (range, 26-29 weeks) and mean birth weight was 1047 g (range, 780-1500 g). Mean gestational age at the time of injection was 35.4 weeks (range, 32-38 weeks). In all eyes, plus disease disappeared completely within 2 weeks and VH and/or RH was absorbed at last follow-up. None of the eyes developed unfavorable structural outcomes. No eyes needed additional injection or laser treatment. No major systemic or ocular complications were observed. Conclusion: In this small series of patients, intravitreal injection of bevacizumab was effective for treatment of severe retinopathy of prematurity associated with vitreous or retinal hemorrhage.


Related Articles

  • Development of Multiple Subretinal Hemorrhages During Diode Laser Supplementation for Retinopathy of Prematurity. Mavrofrides, Elias C.; Berrocal, Audina M.; Murray, Timothy G. // Journal of Pediatric Ophthalmology & Strabismus;Mar/Apr2006, Vol. 43 Issue 2, p110 

    A premature infant had subretinal hemorrhages in one eye after laser ablation for threshold retinopathy of prematurity. We postulate that subretinal hemorrhages occur from trauma to the microvasculature secondary to globe manipulation during scleral depression at the time of laser treatment.

  • Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Roohipoor, Ramak; Ghasemi, Hamed; Ghassemi, Fariba; Karkhaneh, Reza; Riazi-Esfahani, Mohammad; Nili-Ahmadabadi, Mehdi // Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2011, Vol. 249 Issue 9, p1295 

    Background: To evaluate the results of intravitreal bevacizumab in terms of regression of retinopathy of prematurity (ROP). Methods: In this interventional case series, 12 eyes from January 2007 to December 2008 were included. Two groups of patients were considered. Group 1 included those ROP...

  • Spontaneous Resolution of Stage 4B Retinopathy of Prematurity. Nayak, Harish; Lim, May Kim; Watts, Patrick // Journal of Pediatric Ophthalmology & Strabismus;May/Jun2009, Vol. 46 Issue 3, p178 

    An unfavorable outcome occurs in 31% of cases of treated severe threshold retinopathy of prematurity (ROP) and includes a retinal detachment of the posterior pole. Early treatment with laser of high risk prethreshold or type 1 ROP has significantly reduced this complication. However, despite...

  • The earliest case of retinopathy of prematurity? Cuthbertson, F. M.; Bishop, F.; Dabbs, T. R. // Eye;Mar2004, Vol. 18 Issue 3, p314 

    Retinopathy of prematurity (ROP) is a well- recognized condition in premature babies born today and in the recent past. One would not normally expect to come across evidence of its existence among older patients. We present a case of apparent regressed ROP in a lady born in May 1939, prior to...

  • Retinopathy of prematurity: is it time to change screening limits in Lithuania? SirtautienÄ—, Rasa; BagdonienÄ—, Rasa // Acta Medica Lituanica;2006, Vol. 13 Issue 3, p161 

    Background: National guidelines of screening for Retinopathy of prematurity in Lithuania were published in 1998. The upper limits were gestational age 35 weeks and / or birth weight 2500 g. The aim of the study was to determine the possibility of restricting the inclusion criteria for screening....

  • Analysis of risk factors for the development of retinopathy of prematurity in preterm infants at a tertiary referral hospital in South India. Murthy, Krishna R.; Babu, Kalpana; Benakappa, Naveen; Murthy, Praveen R.; Nagendra; Niranjan // Acta Medica Lituanica;2006, Vol. 13 Issue 3, p147 

    Background: With the advances in neonatal care, more and more very low birth weight and short gestation age babies are surviving. Along with this population, the incidence and morbidity of retinopathy of prematurity (ROP) is increasing. Analysis of causative factors is imperative. Materials and...

  • Results of screening and treatment of retinopathy of prematurity over a 10-year period in one neonatal unit of Bulgaria. Nikolova, Svetla; Adams, G. G. W.; Kontrova, Evgenia; Tsvetkova, Snezhinka; Dokova, Klara; Draganov, Dragomir // Acta Medica Lituanica;2006, Vol. 13 Issue 3, p157 

    Background: This study reports the screening and treatment for ROP over a period of 10 years at the Specialized Eye Hospital, Varna, Bulgaria. Materials and methods: Retrospective case note review, between 1996 and 2005, of 686 premature babies screened for ROP in the neonatal unit of the...

  • The Emergence of Retinopathy of Prematurity in Guatemala. Sanchez, M.E.; Andrews, B.J.; Karr, D.; Lansingh, V.; Winthrop, Kevin L. // Journal of Pediatric Ophthalmology & Strabismus;May/Jun2010, Vol. 47 Issue 3, pe1 

    Retinopathy of prematurity is an emerging cause of blindness in Latin America. In 2007, the authors examined 88 consecutive infants in Guatemala City, Guatemala, who met the screening criteria for retinopathy of prematurity; 14 (16%) had either "plus" or stage V disease. The incidence of...

  • Avastin May Offer ROP Treatment.  // Review of Ophthalmology;Mar2011, Vol. 18 Issue 3, p10 

    The article reviews the article "Avastin May Offer ROP Treatment" which appeared in the "New England Journal of Medicine" in February 17, 2011.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics